Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sleep and circadian rhythm disruption addressed with new Oxford spinout Circadian

Clinical Trials Research

Circadian Therapeutics, a life sciences spinout of Oxford University, has been established to identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Alarm clock on a bed © Pollar SD - Shutterstock

Today, there are no safe, effective and fast-acting treatments that provide benefit to patients through modulation of circadian rhythms.

To address this, Circadian Therapeutics has identified drug candidates and is looking to study their effects on circadian rhythms in clinical trials. Simultaneously, the company is aiming to replace hospital-based, expensive diagnostics through the development of a home-based ambulatory electroencephalogram (EEG) device that will provide accurate and minimally intrusive measurement of brain function and circadian rhythms. The home-based monitoring of patients is vastly more cost effective and enables patient monitoring at scale, allowing for more precise and personalised medication. The combination of such products and technologies could be used for interventions across the health spectrum.

Read more